Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL93262 | 0.93 | FDPS (0.34) | FDPS | |
| SCHEMBL2109067 | 0.91 | GGPS1 (0.38) | FDPS | |
| SCHEMBL93145 | 0.91 | GGPS1 (0.38) | FDPS | |
| SCHEMBL2110487 | 0.91 | GGPS1 (0.38) | FDPS | |
| SCHEMBL2110792 | 0.91 | GGPS1 (0.38) | FDPS | |
| SCHEMBL2107758 | 0.91 | GGPS1 (0.38) | FDPS | |
| SCHEMBL2111010 | 0.91 | GGPS1 (0.38) | FDPS | |
| SCHEMBL93197 | 0.91 | GGPS1 (0.38) | FDPS | |
| SCHEMBL93253 | 0.85 | — | — | |
| SCHEMBL276522 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114014878-B | Conjugated alkenyl zinc reagent, preparation method and application thereof | 南开大学 | 2024-06-07 | — | — | CN | claimed |
| CN-116535439-B | Cyclopropane skeleton monophosphine ligand and palladium complex thereof, and preparation method and application thereof | 南开大学 | 2024-05-28 | — | — | CN | claimed |
| CN-116535439-A | Cyclopropane skeleton monophosphine ligand and palladium complex thereof, and preparation method and application thereof | 南开大学 | 2023-08-04 | — | — | CN | claimed |
| WO-2023142725-A1 | CYCLOPROPANE SKELETON MONOPHOSPHINE LIGAND AND PALLADIUM COMPLEX THEREOF AS WELL AS PREPARATION METHOD AND USE THEREOF | 南开大学 | 2023-08-03 | — | — | WO | claimed |
| CN-116003462-A | Silicon-based substituted chiral amine and preparation method and application thereof | 南开大学 | 2023-04-25 | — | — | CN | claimed |
| CN-115850328-A | Diphosphine ligand with cyclopropane skeleton and cobalt complex thereof, preparation method and application | 南开大学 | 2023-03-28 | — | — | CN | claimed |
| US-20220162219-A1 | Chiral Bisamino-Ether Compounds, And Method of Preparation and Use Thereof | UNIV JINAN (CN) | 2022-05-26 | — | — | US | claimed |
| CN-114249725-A | Preparation method and application of 2-imine-9-aryl substituted phenanthroline and iron complex thereof | 南开大学 | 2022-03-29 | — | — | CN | claimed |
| CN-114014879-A | Optically active biaryl borane adduct and preparation method and application thereof | 南开大学 | 2022-02-08 | — | — | CN | claimed |
| CN-114014878-A | Novel conjugated alkenyl zinc reagent, preparation method and application thereof | 南开大学 | 2022-02-08 | — | — | CN | claimed |
| EP-2275398-B1 | APPLICATION OF AN IRIDIUM COMPLEX IN ASYMMETRIC CATALYTIC HYDROGENATION OF AN UNSATURATED CARBOXYLIC ACID | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2016-05-04 | — | — | EP | claimed |
| US-9108995-B2 | Spirobenzylamine-phosphine, preparation method therefor and use thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2015-08-18 | — | — | US | claimed |
| EP-2272853-B1 | SPIRO PHOSPHORUS-OXAZOLINE, SYNTHESIS AND USE THEREOF | ZHEJIANG JIUZHOU PHARM CO LTD (CN) | 2014-08-27 | — | — | EP | claimed |
| US-20140194638-A1 | Spirobenzylamine-Phosphine, Preparation Method Therefor And Use Thereof | ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD. (CN) | 2014-07-10 | — | — | US | claimed |
| EP-2752419-A1 | SPIROBENZYLAMINE-PHOSPHINE, PREPARATION METHOD THEREFOR AND USE THEREOF | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2014-07-09 | — | — | EP | claimed |
| US-8450493-B2 | Spiro phosphine-oxazoline, preparation method and application thereof | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2013-05-28 | — | — | US | claimed |
| US-20110118472-A1 | Spiro Phosphine-Oxazoline, Preparation Method and Application thereof | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-05-19 | — | — | US | claimed |
| US-20110092732-A1 | APPLICATION OF IRIDIUM COMPLEXES IN ASYMMETRIC CATALYTIC HYDROGENATION OF UNSATURATED CARBOXYLIC ACIDS | Zheijiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-04-21 | — | — | US | claimed |
| EP-2275398-A1 | APPLICATION OF THE IRIDIUM COMPLEX IN ASYMMETRIC CATALYTIC HYDROGENATION FOR UNSATURATED CARBOXYLIC ACID | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-01-19 | — | — | EP | claimed |
| EP-2272853-A1 | SPIRO PHOSPHORUS-OXAZOLINE, SYNTHESIS AND USE THEREOF | Zhejiang Jiuzhou Pharmaceutical Co., Ltd. (CN) | 2011-01-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092732-A1 | APPLICATION OF IRIDIUM COMPLEXES IN ASYMMETRIC CATALYTIC HYDROGENATION OF UNSATURATED CARBOXYLIC ACIDS | HDHD5, ELOVL5, FASN | FDPS 738/4885 |
| US-20220162219-A1 | Chiral Bisamino-Ether Compounds, And Method of Preparation and Use Thereof | FHIT, BCAT1, BCAT2 | FDPS 80/4885 |
| US-20140194638-A1 | Spirobenzylamine-Phosphine, Preparation Method Therefor And Use Thereof | FAR1, WEE1, ALDH7A1 | FDPS 78/4885 |
| US-20110118472-A1 | Spiro Phosphine-Oxazoline, Preparation Method and Application thereof | ADH1A, ADH1C, ALDH7A1 | FDPS 2290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.